Quantification of meclizine in human plasma by high performance liquid chromatography–mass spectrometry

Wang, Zhijun; Qian, Shuai; Zhang, Qizhi; Chow, Moses S.S.

doi:10.1016/j.jchromb.2010.11.022

Cited by 18 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incubation mixture was vortexed for 1 minute and then centrifuged at 10 000 rpm for 5 minutes. An aliquot of the supernatant was analyzed using the HPLC‐MS/MS method to detect the residual meclizine 11 . The velocity of reaction was expressed as the amount of meclizine disappeared for a unit of time.…”

Section: Methodsmentioning

confidence: 99%

“…The plasma concentration of meclizine was determined using a validated HPLC-MS/MS method. 11 The plasma concentration-time data were analyzed by noncompartmental method (with the aid of WinNonlin software, version 2.1, SCI). The following pharmacokinetic parameters were generated: sequence, subject (nested in sequence), period, and treatment.…”

Section: Clinical Pharmacokinetic Study Protocolmentioning

confidence: 99%

“…An aliquot of the supernatant was analyzed using the HPLC-MS/MS method to detect the residual meclizine. 11 The velocity of reaction was expressed as the amount of meclizine disappeared for a unit of time. The samples were prepared in triplicate, and data were expressed as mean ± standard deviation (SD).…”

Section: Metabolism Studymentioning

confidence: 99%

See 2 more Smart Citations

Meclizine Metabolism and Pharmacokinetics: Formulation on Its Absorption

Wang

Lee²,

Pearce

et al. 2012

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Meclizine, an antihistamine, has been widely used for prophylactic treatment and management of motion sickness. However, the onset of action of meclizine was about 1 hour for the treatment of motion sickness and vertigo. A new suspension formulation of meclizine (MOS) was developed with the intention to achieve a rapid effect. To investigate the pharmacokinetics of the new MOS formulation versus the marketed meclizine oral tablet (MOT), a phase 1 pharmacokinetic study was performed in 20 healthy volunteers. In addition, an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme was also performed to determine the metabolic pathway in the human body. The plasma concentration of MOS appeared more rapidly in comparison to the MOT. The geometric mean ratios (90% confidence interval) of AUC(0-24) and AUC(0-∞) indicated no significant difference in bioavailability between the 2 formulations. CYP2D6 was found to be the dominant enzyme for metabolism of meclizine, and its genetic polymorphism could contribute to the large interindividual variability. In view of the similar bioavailability with a much shorter peak time of the plasma meclizine concentration from the MOS formulation, this new formulation is expected to produce a much quicker onset of action when used for the management of motion sickness.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Clinical Pharmacokinetic Study Protocolmentioning

confidence: 99%

See 1 more Smart Citation

Meclizine Metabolism and Pharmacokinetics: Formulation on Its Absorption

Wang

Lee²,

Pearce

et al. 2012

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chromatographic conditions: The plasma concentration of MCZ HCl was determined using a modified HPLC-MS/MS method of Wang et al [15] for the determination of MCZ HCl in plasma. The HPLC apparatus consisted of isocratic pump LC-10 AS and a UV/VIS detector SPD-10A connected to a C-R6A Integrator (Shimadzu, Koyoto, Japan).…”

Section: Assay Of Mcz Hcl In Human Plasmamentioning

confidence: 99%

Formulation, Development and Evaluation of Meclozine Hydrochloride Microspheres

Kharshoum¹,

Abou-Taleb²

2015

J Bioequiv Availab

View full text Add to dashboard Cite

“…The validity of the assay method was assessed in terms of linearity, sensitivity, precision, accuracy, recovery, dilution integrity and stability. The QC samples at three concentration levels of low, medium and high concentrations (LQC, MQC and HQC, respectively) as well as sample of lower limit of quantification (LLOQ) were utilized and analyzed for method validation [10] , [11] , [12] .…”

Section: Materials and Instrumentmentioning

confidence: 99%

Quantification and pharmacokinetic study of tumor-targeting agent MHI148-clorgyline amide in mouse plasma using liquid chromatography-electrospray ionization tandem mass spectrometry

Wang

Olenyuk

Shih

et al. 2018

Journal of Pharmaceutical Analysis

Self Cite

View full text Add to dashboard Cite

A high-performance liquid chromatography-electrospray ionization tandem mass spectrometric (HPLC-ESI-MS/MS) method was developed for the quantification of MHI148-clorgyline amide (NMI-amide), a novel tumor-targeting monoamine oxidase A inhibitor, in mouse plasma. The method was validated in terms of sensitivity, precision, accuracy, recovery and stability and then applied to a pharmacokinetic study of NMI-amide in mice following intravenous administration. NMI-amide together with the internal standard (IS), MHI-148, was extracted by protein precipitation using acetonitrile. Multiple reaction monitoring was used for quantification of NMI-amide by detecting m/z transition of 491.2–361.9, and 685.3–258.2 for NMI-amide and the IS, respectively. The lower limit of quantification (LLOQ) of the HPLC–MS/MS method for NMI-amide was 0.005 μg/mL and the linear calibration curve was acquired with R2 > 0.99 in the concentration range of 0.005–2 μg/mL. The intra- and inter-day precisions of the assay were assessed by percentage of the coefficient of variations, which was within 9.8% at LLOQ and 14.0% for other quality control samples, whereas the mean accuracy ranged from 86.8% to 113.2%. The samples were stable under storage and experimental conditions. This method was successfully applied to a pharmacokinetic study in mice following intravenous administration of 5 mg/kg NMI-amide.

show abstract

Quantification of meclizine in human plasma by high performance liquid chromatography–mass spectrometry

Cited by 18 publications

References 7 publications

Meclizine Metabolism and Pharmacokinetics: Formulation on Its Absorption

Meclizine Metabolism and Pharmacokinetics: Formulation on Its Absorption

Formulation, Development and Evaluation of Meclozine Hydrochloride Microspheres

Quantification and pharmacokinetic study of tumor-targeting agent MHI148-clorgyline amide in mouse plasma using liquid chromatography-electrospray ionization tandem mass spectrometry

Contact Info

Product

Resources

About